Award supports design and preclinical testing of
Pulmonary Flow Restrictor for Congenital Heart Disease
SAN
DIEGO, May 1, 2024 /PRNewswire/ -- Starlight
Cardiovascular, Inc., a company developing pediatric cardiovascular
medical devices, announced that it has been awarded a Small
Business Innovation Research (SBIR) Phase II grant from the
National Heart, Lung, and Blood Institute (NHLBI) of the National
Institutes of Health (NIH) to advance development of its Pulmonary
Flow Restrictor. The award will provide $1,999,870 to
support preclinical testing of a device that is designed to prevent
detrimental over-circulation to the lungs in babies born with
Congenital Heart Disease (CHD).
CHD is the most common type of birth defect and affects 1.3
million babies born each year worldwide. Many babies born with
complex CHD require open-heart surgery performed on cardiopulmonary
bypass within the first two weeks of life. Starlight Cardiovascular
is developing Pulmonary Artery Flow Restrictors as a
minimally-invasive alternative to open-chest, surgical pulmonary
artery banding.
Starlight's flow restrictor devices are delivered via a small
catheter and can be expanded to address the dynamic needs of a
growing baby with CHD. "I am thrilled that the NIH has granted
Starlight important funds to continue the development of pulmonary
flow restrictors," expressed Dr. Mark Galantowicz, Chief of
Cardiothoracic Surgery and Director of The Heart Center at
Nationwide Children's Hospital. "Not only will this new device help
improve the outcomes for babies with Hypoplastic Left Heart
Syndrome undergoing a hybrid procedure, but these innovative
Pulmonary Flow Restrictors will open up a myriad of other
applications to the benefit of children with Congenital Heart
Disease."
This grant is supported by the National Heart, Lung, and Blood
Institute of the National Institutes of Health under Award Number
R44HL162218. The content of this press release is solely the
responsibility of the author and does not necessarily represent the
official views of the NIH.
About Starlight Cardiovascular
Starlight Cardiovascular is a preclinical stage medical
technology company developing a portfolio of devices to address
pediatric Congenital Heart Disease.
www.starlightcardio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/starlight-cardiovascular-awarded-2m-nih-sbir-phase-ii-grant-to-develop-pediatric-cardiology-device-302132314.html
SOURCE Starlight Cardiovascular